Benitec Biopharma (NASDAQ:BNTC – Get Free Report) and LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.
Analyst Ratings
This is a summary of current ratings and price targets for Benitec Biopharma and LENZ Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Benitec Biopharma | 1 | 2 | 6 | 0 | 2.56 |
| LENZ Therapeutics | 2 | 1 | 5 | 0 | 2.38 |
Benitec Biopharma currently has a consensus price target of $27.00, indicating a potential upside of 135.40%. LENZ Therapeutics has a consensus price target of $29.80, indicating a potential upside of 443.80%. Given LENZ Therapeutics’ higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Benitec Biopharma.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Benitec Biopharma | N/A | -34.82% | -34.11% |
| LENZ Therapeutics | -519.30% | -46.82% | -43.32% |
Volatility and Risk
Benitec Biopharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
Valuation and Earnings
This table compares Benitec Biopharma and LENZ Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Benitec Biopharma | N/A | N/A | -$37.92 million | ($1.14) | -10.06 |
| LENZ Therapeutics | $19.09 million | 9.00 | -$82.13 million | ($3.60) | -1.52 |
Benitec Biopharma has higher earnings, but lower revenue than LENZ Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Benitec Biopharma beats LENZ Therapeutics on 7 of the 13 factors compared between the two stocks.
About Benitec Biopharma
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
